Immunotherapy, with an increasing number of therapeutic dimensions, is becoming an
important mode of treatment for cancer patients. The inhibition of immune checkpoints …

In spite of the remarkable progress in basic and preclinical studies of acute myeloid
leukemia (AML), the five-year survival rate of AML patients remains poor, highlighting the …

Despite considerable progress has been achieved in the treatment of acute myeloid
leukemia over the past decades, relapse remains a major problem. Novel therapeutic …

Allogeneic hematopoietic stem cell transplantation (alloSCT) is an important curative
therapy for high-risk hematological malignancies, but the development of severe and/or …

Co-inhibitory receptors (IRs) are molecules that protect host against autoimmune reactions
and maintain peripheral self-tolerance, playing an essential role in maintaining immune …

AML is the most common blood cancer in adults with a high relapse and an overall poor
survival rate. NK cells have been demonstrated to have the capacity to eradicate AML blast …

Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%,
emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be …

Natural killer (NK) cells have the innate ability to kill cancer cells, however, tumor cells may
acquire the capability of evading the immune response, thereby leading to malignancies …

DNAM-1 is a major NK cell activating receptor and, together with NKG2D and NCRs, by
binding specific ligands, strongly contributes to mediating the killing of tumor or virus …

Simple Summary The emergence of immunotherapy for cancer treatment bears
considerable clinical promise. The role of NK cells in tumor immunosurveillance and their …